Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 476 - 500 of 14696 in total
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
Matched Description: … receptors, lemborexant and other orexin antagonists (e.g. ... receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and ... potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and
Matched Categories: … Hypnotics and Sedatives ... Sleep Initiation and Maintenance Disorders …
Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Approved
Investigational
Matched Description: … + influx, and eventually increases insulin release. ... This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2 …
Matched Categories: … Alimentary Tract and Metabolism …
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha...
Approved
Investigational
Withdrawn
Matched Description: … A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn ... It has been reintroduced and used for a number of inflammatory disorders and cancers. ... inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Approved
Investigational
Matched Description: … An antiandrogen with about the same potency as cyproterone in rodent and canine species. …
Matched Categories: … Antiandrogens, non-steroidal ... Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine...
Approved
Investigational
Matched Description: … indolent B-cell non-Hodgkin lymphoma (NHL). ... a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and ... Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line...
Approved
Matched Description: … Evolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver ... It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia …
Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Approved
Investigational
Matched Categories: … Analgesics, Non-Narcotic …
Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment...
Approved
Matched Description: … Doxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured …
Matched Categories: … Diet, Food, and Nutrition ... Vitamin D and Analogues ... Sex Hormones and Insulins …
Approved
Experimental
Disperse Blue 106 is used in allergenic testing.
Approved
Experimental
Matched Iupac: … 2-[ethyl({3-methyl-4-[(E)-2-(5-nitro-1,3-thiazol-2-yl)diazen-1-yl]phenyl})amino]ethan-1-ol
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are...
Approved
Investigational
Matched Description: … genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and ... [L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21 ... A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased …
Matched Categories: … bempedoic acid and ezetimibe ... Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia …
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Approved
Withdrawn
Matched Description: … It is a yellow, odorless, non-hygroscopic, crystalline compound. …
Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active...
Approved
Investigational
Matched Description: … [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for ... hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and ... A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and
Matched Categories: … Cellular and Gene Therapy ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells.[A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or...
Approved
Withdrawn
Matched Description: … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA ... Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and ... under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and
Matched Categories: … Skin and Mucous Membrane Agents ... Amino Acids, Peptides, and Proteins ... Agents Against Leishmaniasis and Trypanosomiasis ... Antineoplastic and Immunomodulating Agents ... Antiparasitic Products, Insecticides and Repellents …
Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for...
Approved
Investigational
Matched Description: … Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. ... [Label] The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture …
Matched Categories: … meropenem and vaborbactam …
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has...
Approved
Investigational
Matched Description: … humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and ... As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its ... has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … [L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. ... Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and DB09301 , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting...
Approved
Withdrawn
Matched Description: … The active constituents are heparan, dermatan and [DB09301] [T28], and they are isolated from the porcine ... in the United States however it is available in several other countries including European countries and ... Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including...
Approved
Matched Description: … Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. ... to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and ... [L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and
Matched Categories: … Non-selective Alfa-adrenergic Blocking Agents …
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Description: … This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection ... and reducing the signs and symptoms in patients 2 years old and older. ... It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a …
Approved
Experimental
Matched Categories: … Calcium-Regulating Hormones and Agents ... Non-Selective Calcium Channel Blockers …
Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about...
Approved
Nutraceutical
Vet approved
Matched Description: … , fertility and reproduction. ... Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. ... Lerner of Yale University is credited for naming the hormone and for defining its chemical structure …
Matched Categories: … Hypnotics and Sedatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Approved
Investigational
Matched Iupac: … 8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol
Matched Description: … It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Ursodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool.[A256272,A256277] UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years.[A256267,A256463] UDCA was first characterized...
Approved
Investigational
Matched Description: … [A256267,A256463] UDCA was first characterized in the bile of the Chinese black bear and is formed by ... [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary …
Matched Categories: … Bile Acids and Salts ... Bile and Liver Therapy ... Bile acids and derivatives ... Alimentary Tract and Metabolism ... Cholagogues and Choleretics …
A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Approved
Matched Description: … It also tends to lower blood pressure and increase potassium loss. …
Matched Categories: … Non Potassium Sparing Diuretics ... Genito Urinary System and Sex Hormones ... metolazone and potassium-sparing agents ... Gynecological Antiinfectives and Antiseptics ... Low-Ceiling Diuretics and Potassium-Sparing Agents …
Displaying drugs 476 - 500 of 14696 in total